The application provides methods for the treatment of
migraine for patients that are poor responders to triptan treatments. Some embodiments provide methods for treating or reducing
migraine in patients that do not adequately respond to triptan treatments comprising the step of administering an effective amount of CGRP antagonists; for example, ubrogepant or atogepant, or a pharmaceutically acceptable salt, ester or
prodrug thereof.